RetaBem 120mg/powder 1 vial

Description

RetaBem Retatrutide is a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. It is being developed primarily for obesity, type 2 diabetes, and related metabolic disorders.

Mechanism of Action

RetaBem Retatrutide acts on three receptors:

• GLP-1 receptor (Glucagon-like peptide-1):
  • Enhances insulin secretion
  • Reduces glucagon secretion
  • Slows gastric emptying
  • Suppresses appetite
• GIP receptor (Glucose-dependent insulinotropic polypeptide):
  • Enhances insulin secretion in a glucose-dependent manner
  • Synergistic with GLP-1 in improving glycemic control
• Glucagon receptor:
  • Increases energy expenditure
  • May promote fat oxidation
  • Can raise blood glucose, but this effect is counterbalanced by GLP-1 and GIP activity

The combined action mimics postprandial hormone responses and enhances weight loss and metabolic improvement more significantly than GLP-1 or GLP-1/GIP therapies alone.

Clinical Effects and Benefits

• Weight Loss: In Phase 2 trials, retatrutide resulted in up to 24.2% weight reduction over 48 weeks (at the 12 mg dose), approaching bariatric surgery levels.
• Glycemic Control: Significant reductions in HbA1c, fasting glucose, and insulin resistance.
• Liver Fat: Marked improvement in hepatic steatosis and potential in treating NASH.
• Metabolic Health: Improvements in lipids, blood pressure, and markers of inflammation.

Comparison with Semaglutide and Tirzepatide

Feature	Retatrutide	Semaglutide	Tirzepatide
Class	GLP-1/GIP/Glucagon agonist	GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Receptor Targets	GLP-1, GIP, Glucagon	GLP-1 only	GLP-1, GIP
Weight Loss (avg)	17–24% (dose-dependent)	~15% (2.4 mg for obesity)	20–22.5% (15 mg dose)
Glycemic Improvement	Strong	Strong	Very strong
Onset of Action	Slower titration due to GI effects	Moderate	Moderate
GI Side Effects	High at higher doses	Moderate to high	Moderate to high
Energy Expenditure	↑ due to glucagon receptor action	Neutral	Possibly slight increase
Liver Fat Reduction	Significant	Moderate	Moderate to significant
Current Approval	Phase 3 (as of 2025)	FDA-approved (T2DM, obesity)	FDA-approved (T2DM, obesity)

Contraindications

Same general contraindications as other GLP-1-based therapies, though expanded studies are ongoing.

• Personal/family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pancreatitis history
• Severe gastrointestinal disease (e.g., gastroparesis)
• Pregnancy and lactation
• Hypersensitivity to components

Side Effects

• Common:
  • Nausea, vomiting, diarrhea, constipation
  • Decreased appetite
  • Headache, fatigue
• Less Common:
  • Gallbladder issues
  • Elevated heart rate
  • Hypoglycemia (mostly in combination with insulin or sulfonylureas)

Anti-Aging / Longevity (Fosaging) Potential

Retatrutide is not marketed specifically as an anti-aging drug, but its metabolic benefits may impact longevity:

• Reduces visceral fat and systemic inflammation
• Improves insulin sensitivity, reducing cellular aging from glycation
• Supports cardiovascular and hepatic health
• May reduce biological age indirectly via better metabolic markers and body composition

Though human data is lacking, its mechanisms intersect with those linked to healthspan (reduced risk of metabolic syndrome, NASH, atherosclerosis).

Conclusion

Retatrutide shows promise as a next-generation obesity and metabolic disease treatment, outperforming semaglutide and tirzepatide in weight loss and liver fat reduction. With its triple-agonist action, it offers a powerful tool for both weight loss and potentially broader metabolic and aging-related applications—though long-term safety, real-world data, and aging-specific studies are still pending.

As of 2025, Retatrutide is still in clinical trials (Phase 3), and while a finalized, commercially approved injection protocol does not yet exist, we can reference the clinical trial protocols for guidance.

Retatrutide Injection Protocol (Based on Phase 2 Clinical Trials)

Route of Administration:

• Subcutaneous (SC) injection

Frequency:

• Once weekly

Sites:

• Abdomen, thigh, or upper arm (rotate injection sites)

Dosing Schedule (Titration Protocol Used in Trials)

To reduce gastrointestinal side effects, gradual dose escalation was used:

Week	Dose (mg)	Notes
1–4	2 mg	Initiation phase
5–8	4 mg	Gradual escalation
9–12	8 mg	Continued titration
13+	8–12 mg	Target maintenance dose (based on tolerability and goal)

• Some trial arms escalated to 12 mg weekly after 12+ weeks.
• The maximum dose in Phase 2 studies was 12 mg once weekly, which showed the most significant weight loss.

Formulation and Preparation

• Prefilled pen (planned for commercial use, similar to semaglutide/tirzepatide)
• Refrigeration required (keep at 2°C to 8°C)
• Allow to come to room temperature before injection (30 min)

Important Administration Guidelines

• Inject on the same day each week
• If a dose is missed:
  • Can be taken within 4 days of missed dose
  • Otherwise, skip and resume next scheduled dose
• Do not inject into irritated, red, or scarred skin

Monitoring During Therapy

• Weight and BMI
• HbA